Neuroaptamer

Neuroaptamer group members publications:

Werner, S.J., Martin, S.W., Paterson, A.W.J. & Milton, N.G.N. (2018) Effects of the cannabinoid receptor antagonist hemopressin on amyloid-β induced toxicity in mouse Neuro-2a neuroblastoma cells. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol18Issue1abst224P.pdf

Cussell, P.J., Howe, M.S., Gomez Escalada, M., Milton, N.G.N. & Paterson, A.W.J. (2018) Formyl peptide receptor agonist FPRa14 induced differentiation of Neuro2a mouse neuroblastoma cells in culture. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol18Issue1abst228P.pdf

Milton, N.G.N. (2017) Effects of the CB1 cannabinoid receptor antagonist AM281 on kissorphin protection against amyloid-β neurotoxicity. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol17Issue1abst030P.pdf

Werner, S.J., Martin, S.W., Paterson, A.W.J. & Milton, N.G.N. (2017) Effects of RVD-hemopressin on amyloid-β induced toxicity in SH-SY5Y neuronal cell culture. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol17Issue1abst020P.pdf

Milton, N. (2017) Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. United Kingdom Patent Publication Number GB 2493313 (B).

Chilumuri, A., Markiv, A. & Milton, N.G.N. (2014) Immunocytochemical staining of endogenous nuclear proteins with the HIS-1 anti-poly-histidine monoclonal antibody: apotential source of error in His-tagged protein detection. Acta Histochemica, 1161022-1028.

Milton, N.G.N. & Harris, J.R. (2014) Chapter 23 - Polymorphism of Amyloid Fibrils and their Complexes with Catalase. In: Bio-nanoimaging: Protein Misfolding and Aggregation. Eds V.N. Uversky & Y.L. Lyubchenko, Academic Press, Boston, pp 255-262.

Chilumuri, A., Odell, M. & Milton, N.G.N. (2013) Benzothiazole aniline-tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro. ACS Chem. Neurosci.4, 1501-1512.

Chilumuri, A., Odell, M. & Milton, N. (2013) The neuroprotective role of catalase overexpression in SH-SY5Y cells against beta-amyloid and H2O2 toxicity. Alzheimer's & Dementia: The Journal of the Alzheimer's Association9 (4 (Supplement)), P361.

Chilumuri, A. & Milton, N.G.N. (2013) The role of neurotransmitters in protection against amyloid-β toxicity by KiSS-1 overexpression in SH-SY5Y neurons.ISRN Neuroscience, 2013, 253210.

Chilumuri, A., Ashioti, M., Nercessian, A.N. & Milton, N.G.N. (2013) Immunolocalization of kisspeptin associated with amyloid-ß deposits in the pons of an Alzheimer's disease patient. J. Neurodegen. Dis., 2013, 879710.

Milton, N. (2013) Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. United Kingdom Patent Application Publication Number GB 2493313 (A).

Milton, N.G.N. & Harris, J.R. (2013) Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide. Micron44, 246-253.

Harris, J.R. & Milton, N.G.N. (2012) Introduction and technical survey: protein aggregation and fibrillogenesis. Subcell. Biochem., 65, 3-25.

Milton, N.G.N. (2012) In vitro activities of Kissorphin, a novel hexapeptide KiSS-1 derivative, in neuronal cells. J. Amino Acids2012, 691463.

Milton, N.G.N., Chilumuri, A., Rocha-Ferreira, E., Nercessian, A.N. & Ashioti, M. (2012) Kisspeptin prevention of amyloid-ß peptide neurotoxicity in vitro. ACS Chem. Neurosci., 3, 706-719.

Milton, N. (2012) Kissorphin, a hexapeptide derivative of Kisspeptin, acts via Neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no Gonadotrophin-Releasing-Hormone releasing activity. Endocrine Abstracts28, OC2.3.

Milton, N. (2011) Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. International Patent Application Publication Number WO 2011/144714 (A1).

Milton, N. (2011) Kisspeptin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. European Patent Application Publication Number EP2388012 (A1).

Milton, N.G.N. & Harris, J.R. (2010) Human islet amyloid polypeptide fibril binding to catalase: a transmission electron microscopy and microplate study. The Scientific World Journal, 10, 879-893.

Harris, J.R. & Milton, N.G.N. (2010) Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell. Biochem., 51, 47-75.

Milton, N.G.N. & Harris, J.R. (2009) Polymorphism of Amyloid-ß fibrils and its effects on Human Erythrocyte Catalase binding. Micron40, 800-810.

Milton, N.G.N. (2008) Homocysteine inhibits hydrogen peroxide breakdown by Catalase. The Open Enzyme Inhibition Journal1, 34-41.

Milton, N.G.N. (2006) Anti-sense Peptides. In Cell Biology Protocols, Eds D. Rickwood, J. Graham & J.R. Harris, Wiley, London, pp 353-358.

Milton, N.G.N. (2006) Interactions between amyloid-ß and enzymes. In Cell Biology Protocols, Eds D. Rickwood, J. Graham & J.R. Harris, Wiley, London pp 359-363.

Milton, N.G.N. (2006) Amyloid-ß phosphorylation. In Cell Biology Protocols, Eds D. Rickwood, J. Graham & J.R. Harris, Wiley, London pp 364-368.

Milton, N.G.N. (2005) Phosphorylated amyloid-ß: the toxic intermediate in Alzheimer's disease neurodegeneration. Subcell. Biochem., 38, 381-402.

Milton, N.G.N. (2005) Phosphorylated Amyloid-ß 1-43 protein and its use in the treatment of Alzheimer's disease. European Patent Application Publication Number EP1538163.

Milton, N.G.N. (2004) Role of hydrogen peroxide in the aetiology of Alzheimer's Disease: implications for treatment. Drugs Aging, 21, 81-100.

Milton, N.G.N. (2004) Peptides for use in the treatment of Alzheimer's disease. United States Patent Application Publication Number US 2004/0072753.

Vincent, I., Nagy, Z., Neve, R., Herrup, K., Milton, N., Smith, M., Wolozin, B., Chen, Y., Lu, K.P., Kinoshita, J., Strobel, G., Hallows, J., Bowser, R., Feinstein, D., Atwood, C., and Maiese, K. (2003) Transcript of Live Discussion: The Cell Cycle in Alzheimer's Disease: Let's Unite Around Division. J. Alzheimers Dis.5, 251-262.

Milton, N.G.N. (2003) Peptides for use in the treatment of Alzheimer's disease. European Patent Application Publication Number EP1363939.

Milton, N.G.N. (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-ß peptide. Neurosci. Lett., 332, 127-130.

Milton, N.G.N. (2002) The amyloid-ß peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity. Neurosci. Lett., 322, 131-133.

Milton, N.G.N. (2002) Peptides for use in the treatment of Alzheimer's disease. International Patent Application Publication Number WO 02/36614.

Milton, N.G.N. (2001) Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer’s amyloid-ß peptide. NeuroToxicology, 22, 767- 774.

Milton, N.G.N. (2001) Phosphorylation of amyloid-ß at the serine 26 residue by human cdc2 kinase. NeuroReport, 12, 3839-3844.

Milton, N.G.N., Mayor, N.P. & Rawlinson, J. (2001) Identification of amyloid-ß binding sites using an antisense peptide approach. NeuroReport12, 2561-2566.

Milton, N.G.N. (1999) Amyloid-ß binds catalase with high affinity and inhibits hydrogen peroxide breakdown. Biochem. J.344, 293-296.